상세 보기
Camizestrant+CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2-advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
- Turner, Nicholas C.;
- Mayer, Erica L.;
- Park, Yeon Hee;
- Janni, Wolfgang;
- Ma, Cynthia X.;
- 외 15명
Citations
WEB OF SCIENCE
0- 제목
- Camizestrant+CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2-advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
- 저자
- Turner, Nicholas C.; Mayer, Erica L.; Park, Yeon Hee; Janni, Wolfgang; Ma, Cynthia X.; Cristofanilli, Massimo; Bianchini, Giampaolo; Kalinsky, Kevin; Iwata, Hiroji; Chia, Stephen K. L.; Fasching, Peter A.; Brufsky, Adam; Nowecki, Zbigniew; Pascual, Javier; Moreau, Lionel; Chen, Shin-Cheh; McClain, Sasha; Fox, Steven; Bartlett, Cynthia Huang; Bidard, Francois Clement
- 발행일
- 2026-02
- 유형
- Meeting Abstract
- 권
- 49
- 페이지
- 11 ~ 11